JCEM Publishes Data from OXiGENE-sponsored Preclinical Study of Combretastatin A4 phosphate / CA4P Triple-Drug Combinations in Anaplastic Thyroid Cancer
August 07, 2007 09:00 ET
|
Oxigene, Inc.
JCEM Publishes Data from OXiGENE-sponsored Preclinical Study of Combretastatin
A4 phosphate / CA4P Triple-Drug Combinations in Anaplastic Thyroid Cancer
Triple-drug combination therapy shows...
OXiGENE Appoints Patricia Walicke, M.D., Ph.D. as Chief Medical Officer
July 31, 2007 09:00 ET
|
Oxigene, Inc.
OXiGENE Appoints Patricia Walicke, M.D., Ph.D. as Chief Medical Officer
Drug Development Veteran to Oversee Clinical Development
WALTHAM, Mass.--(BUSINESS WIRE)--July 31, 2007--Regulatory...
OXiGENE Reports Second Quarter Financial Results and Provides Progress Update
July 25, 2007 09:05 ET
|
Oxigene, Inc.
OXiGENE Reports Second Quarter Financial Results and Provides Progress Update
WALTHAM, Mass.--(BUSINESS WIRE)--July 25, 2007--Regulatory News:
OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a...
OXiGENE Schedules Second Quarter 2007 Earnings Conference Call
July 16, 2007 12:04 ET
|
Oxigene, Inc.
OXiGENE Schedules Second Quarter 2007 Earnings Conference Call
Live Internet Webcast to be Available at www.oxigene.com
WALTHAM, Mass.--(BUSINESS WIRE)--July 16, 2007--Regulatory News:
...
OXiGENE Schedules Second Quarter 2007 Earnings Conference Call
July 16, 2007 09:18 ET
|
Oxigene, Inc.
OXiGENE Schedules Second Quarter 2007 Earnings Conference Call
Live Internet Webcast to be Available at www.oxigene.com
WALTHAM, Mass.--(BUSINESS WIRE)--July 18, 2007--Regulatory News:
...
OXiGENE Begins Pivotal Registration Study for ZYBRESTAT(TM) in Anaplastic Thyroid Cancer
July 11, 2007 15:32 ET
|
Oxigene, Inc.
OXiGENE Begins Pivotal Registration Study for ZYBRESTAT(TM) in Anaplastic
Thyroid Cancer
WALTHAM, Mass.--(BUSINESS WIRE)--July 9, 2007--Regulatory News:
OXiGENE, Inc. (NASDAQ: OXGN, XSSE:...
OXiGENE Adds Two New Directors to Its Board
June 27, 2007 09:03 ET
|
Oxigene, Inc.
OXiGENE Adds Two New Directors to Its Board
WALTHAM, Mass.--(BUSINESS WIRE)--June 27, 2007--Regulatory News:
OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage
biopharmaceutical company...
OXiGENE Abstracts Published in ASCO Program
June 01, 2007 15:45 ET
|
Oxigene, Inc.
OXiGENE Abstracts Published in ASCO Program
-- Phase II Combretastatin A4 Phosphate / CA4P study with
paclitaxel and carboplatin shows safety, anti-tumor activity,
and reduced blood flow
--...
OXiGENE Reaches Agreement with FDA on Special Protocol Assessment for ZYBRESTAT(TM) (CA4P) Phase II/III Pivotal Trial in Anaplastic Thyroid Cancer
May 31, 2007 15:41 ET
|
Oxigene, Inc.
OXiGENE Reaches Agreement with FDA on Special Protocol Assessment for
ZYBRESTAT(TM) (CA4P) Phase II/III Pivotal Trial in Anaplastic Thyroid Cancer
Phase II/III Pivotal Trial Expected to Begin...
OXiGENE Announces a Poster Presentation Highlighting Results from its Study of ZYBRETSTAT™ CA4P in Myopic Macular Degeneration (Study MMD-213) at the 47th Annual Meeting of the Association of Research in Vision and Ophthalmology
May 07, 2007 09:01 ET
|
Oxigene, Inc.
OXiGENE Announces a Poster Presentation Highlighting Results from its Study of
ZYBRETSTAT™ CA4P in Myopic Macular Degeneration (Study MMD-213) at the 47th
Annual Meeting of the Association of Research...